

1 Revised version 2018-03-13

2 **Infection and Immunity**

3

---

4 MINIREVIEW

5 **Are Sphingolipids and Serine Dipeptide Lipids underestimated Virulence**

6 **Factors of *Porphyromonas gingivalis*?**

7 Ingar Olsen,<sup>a</sup> and Frank C. Nichols<sup>b,\*</sup>

8 <sup>a</sup>Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway

9 <sup>b</sup> Department of Oral Health and Diagnostic Sciences of the University of Connecticut School of  
10 Dental Medicine, Farmington, CT, USA

11 <sup>\*</sup>Corresponding author.

12 Address for correspondence to [nichols@uchc.edu](mailto:nichols@uchc.edu)

13 Department of Oral Health and Diagnostic Sciences, MC 1710

14 University of Connecticut School of Dental Medicine

15 263 Farmington Avenue

16 Farmington, CT 06030 USA

17

18

19

20

21     **ABSTRACT**

---

22  
23     The keystone periodontal pathogen *Porphyromonas gingivalis* produces phosphorylated  
24     dihydroceramide lipids (sphingolipids) such as phosphoethanolamine dihydroceramide (PE  
25     DHC) and phosphoglycerol dihydroceramide (PG DHC) lipids. Phosphorylated DHCs (PDHCs)  
26     from *P. gingivalis* can affect a number of mammalian cellular functions such as potentiation of  
27     prostaglandin secretion from gingival fibroblasts, promotion of RANKL-induced  
28     osteoclastogenesis, promotion of apoptosis and enhancement of autoimmunity. In *P. gingivalis*,  
29     these lipids affect anchoring of surface polysaccharides, resistance to oxidative stress and  
30     presentation of surface polysaccharides (anionic polysaccharides and K-antigen capsule). In  
31     addition to phosphorylated dihydroceramide lipids, serine dipeptide lipids of *P. gingivalis* are  
32     implicated in alveolar bone loss in chronic periodontitis through interference with osteoblast  
33     differentiation and function, and promotion of osteoclast activity. As a prerequisite for  
34     designation as bacterial virulence factors, bacterial sphingolipids and serine dipeptide lipids are  
35     recovered in gingival/periodontal tissues, tooth calculus, human blood, vascular tissues and brain.  
36     In addition to *P. gingivalis*, other bacteria of the genera *Bacteroides*, *Parabacteroides*,  
37     *Porphyromonas*, *Tannerella* and *Prevotella* produce sphingolipids and serine dipeptide lipids.  
38     The contribution of PDHCs and serine dipeptide lipids to the pathogenesis of periodontal and  
39     extraoral diseases may be an underappreciated area for microbial-host interaction and should be  
40     more intensively investigated.

41

42     **KEYWORDS:** *P. gingivalis*, virulence factors, sphingolipids, ceramides, periodontitis, extraoral  
43     diseases

44

45

## 46 INTRODUCTION

---

47  
48

49 Sphingolipids, as amphipathic molecules, demonstrate both hydrophobic and hydrophilic  
50 constituents and, as such, have long been considered little more than structural lipid components  
51 of eukaryotic cell membranes. More recent studies, however, have shown that mammalian  
52 sphingolipids such as ceramide (the simplest sphingolipid), sphingosine and sphingosine-1-  
53 phosphate lipids, are central to a number of important biological processes. Mammalian  
54 sphingolipids are known to make complexes with proteins and other cell membrane lipids, often  
55 sterols, to form so-called lipid rafts (1, 2). Lipid rafts are fluctuating nanoscale collections of  
56 sphingolipid, cholesterol and proteins in cell membranes, constituting platforms that operate in  
57 membrane signaling and trafficking. Of note, most bacteria of the Bacteroidetes phylum and a  
58 few bacteria of the Chlorobi phylum (3) produce sphingolipids but only members of the  
59 Bacteroidetes phylum are reported to produce novel serine dipeptide lipids (4-7). These lipid  
60 classes demonstrate amphipathic characteristics and possess important biological properties.  
61 When members of the Bacteroidetes phylum, particularly oral Bacteroidetes, contact human cells,  
62 bacterial sphingolipids and serine lipids may incorporate into the eukaryotic cell membranes  
63 thereby potentially affecting cell function. As an example, lipid raft components are used by the  
64 periodontal pathogen *Porphyromonas gingivalis* (8), for entry into host epithelial cells (9, 10).

65 Chronic periodontitis is manifested as progressive loss of periodontal attachment and alveolar  
66 bone, leading to pathological pocket formation around the teeth. If left untreated, it can lead to  
67 loss of teeth. Chronic periodontitis affects approximately 65 million (47 %) US adults of 30 years  
68 and older (11). Chronic periodontitis has also been associated with extraoral diseases such as  
69 cardiovascular diseases, diabetes, preterm birth, Alzheimer's disease, rheumatoid arthritis and  
70 pancreatic cancer (12-14). The keystone periodontal pathogen *P. gingivalis* produces many  
71 virulence factors of which the major classes include lipopolysaccharide (LPS), a polysaccharide-  
72 rich capsule, gingipains, fimbriae and peptidyl-arginine deiminase. *P. gingivalis* LPS is  
73 considered to be important in bone destruction in periodontitis. However, previous reports have  
74 shown that LPS of *P. gingivalis* is present only in minor amounts in diseased periodontal tissues  
75 from humans (15, 16). In contrast to LPS, *P. gingivalis* dihydroceramides (DHCs) (17, 18) and

76 serine dipeptide lipids (19) are exposed to diseased gingival tissues at levels capable of inducing  
77 an inflammatory response (20).

78 Within the diseased periodontal crevice (pocket), *P. gingivalis* is known to directly contact and  
79 attach to sulcular epithelial cells (21) (**FIGURE 1**), and co-culture of *P. gingivalis* with epithelial  
80 cells reveals an ultrastructural thickening of the merged membranes as *P. gingivalis* is  
81 internalized (22). This cell membrane contact could deliver bacterial lipids directly to the cell  
82 membranes of host epithelial cells. Another mechanism for bacterial lipid entry into cells is  
83 demonstrated by the uptake of total lipids of *P. gingivalis* into human gingival fibroblasts when  
84 cells are exposed to lipid films in culture (20). Therefore, *P. gingivalis* lipids are likely  
85 transferred to cells of gingival tissues either by direct contact with bacteria or by chemical  
86 diffusion from lipid contaminated surfaces of diseased teeth. Either process can lead to  
87 deposition of bacterial lipids into eukaryotic cell membranes, thereby exposing cells, including  
88 lipid rafts, to elevated levels of non-mammalian sphingolipids and serine dipeptide lipids. In  
89 contrast to periodontal Bacteroidetes, gastrointestinal *Bacteroides* are recovered primarily in the  
90 colon (3) but little is known about breakdown of these bacterial sphingolipids in the colon or their  
91 transport within this organ.

92 *P. gingivalis* produces several classes of phosphorylated dihydroceramides (PDHCs) as well as  
93 other novel complex lipids (see **TABLE 1**, **FIGURE 2** and **3**) including serine dipeptide lipids.  
94 The first to be characterized were the sphingolipids which are quite similar but not identical to  
95 mammalian sphingolipids. PDHCs can be detected in, quantitated and distinguished from  
96 eukaryotic sphingolipids using multiple reaction monitoring (MRM)-mass spectrometry (MS)  
97 (23). The sphingoid bases in *P. gingivalis* DHC lipids comprise saturated aliphatic chains of 17,  
98 18 or 19 carbons with *isobranching* of the odd numbered carbon chains (see **FIGURE 2**) (17, 18).  
99 The sphingoid base is designated sphinganine (dihydrophingosine) or dihydroceramide (DHC)  
100 when amide-linked to a fatty acid chain, which in *P. gingivalis* sphingolipids is usually 3-OH  
101 *isobranched* C<sub>17:0</sub> (see **FIGURE 2**) (18). From *P. gingivalis* lipid extracts, three major DHC  
102 species have been recognized: the free DHC, phosphoethanolamine DHC (PE DHC) and  
103 phosphoglycerol DHC (PG DHC) lipids (17, 18). The free DHC lipids are presumed to serve as  
104 precursor core structures for the synthesis of PE DHC and PG DHC lipids (see **FIGURE 2**). The  
105 *isobranched* aliphatic chains of phosphoglycerol dihydroceramides and

106 phosphatidylethanolamines (PEA) of *P. gingivalis* (see FIGURE 2) are thought to be partially  
107 responsible for the bioactivity of these lipids (24). PG DHC can be further modified with the  
108 addition of *iso*branched C<sub>15:0</sub> to the 3-OH group of the dihydroceramide core fatty acid chain  
109 (18). This lipid was later termed substituted (sub) PG DHC but in some prior reports, the term PG  
110 DHC was used instead of sub PG DHC. However, if PG DHC lipids are not substituted with  
111 *iso*C<sub>15:0</sub> or other fatty acids, this class was specifically designated as unsub PG DHC lipids in  
112 previous reports (see FIGURE 2).

113 Contrasted with the structures of PDHC lipids are the serine dipeptide lipids of *P. gingivalis*,  
114 including Lipid 654 and Lipid 430 (FIGURE 3). Lipid 654 of *P. gingivalis*, which is the  
115 dominant serine dipeptide lipid class of *P. gingivalis*, was first described in *Fusobacterium*  
116 *meningosepticum* and was termed flavolin (7). Flavolin was originally reported to be a Toll-  
117 like receptor 4 ligand (4) but recent work has shown that Lipid 654 is a TLR2 ligand rather than a  
118 TLR4 ligand (19, 25). Toll-like receptors are known to recognize exogenous ligands and are  
119 reported to function within lipid rafts (26). Just as with *P. gingivalis* sphingolipids, serine  
120 dipeptide lipids are recovered in diseased periodontal tissues (19) as well as blood (27) and artery  
121 walls of humans (6). Of physiological importance is that the mammalian enzyme phospholipase  
122 A2 (PLA2), typically expressed in chronic inflammatory reactions, hydrolyzed Lipid 654 of *P.*  
123 *gingivalis* to another serine lipid class called Lipid 430 (5, 6). Just as with Lipid 654, Lipid 430  
124 also activated human embryonic kidney cells transfected with human TLR2 and also increased  
125 serum CCL2 (MCP-1) levels in wild type mice but not TLR2 knockout mice (19). However,  
126 mouse osteoblast function and differentiation were markedly inhibited by Lipid 430 regardless of  
127 TLR2 status (25). In this brief review, focus is directed toward sphingolipids and serine  
128 dipeptide lipids of *P. gingivalis*, and their potential roles as virulence factors, particularly as they  
129 relate to bone loss in chronic periodontitis. Sphingolipids in both bacteria and fungi have  
130 previously been reviewed (28).

131

132 **POTENTIATION OF PROSTAGLANDIN SECRETION FROM GINGIVAL  
133 FIBROBLASTS**

134 It is reasonable to suspect that penetration of bacterial lipids into gingival tissues combined with  
135 chronic inflammation can promote destructive periodontitis. *P. gingivalis* total lipids (20), PG  
136 DHC lipids (18) and phosphatidylethanolamine lipids (PEA) (24) promoted interleukin-1 $\beta$  (IL-  
137 1 $\beta$ )-mediated secretion of inflammatory mediators (prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and 6-keto  
138 prostaglandin F<sub>2 $\alpha$</sub> ) from human gingival fibroblasts and changed their cellular morphology in  
139 culture (18, 24). The potentiation of PGE<sub>2</sub> synthesis and secretion from fibroblasts, possibly  
140 mediated through TLR2, could be an important mechanism for *P. gingivalis* to promote  
141 inflammatory reactions and change host responses including osteoclast mediated bone resorption,  
142 thereby promoting tissue breakdown in periodontal disease.

143

#### 144 **PROMOTION OF RANKL-INDUCED OSTEOCLASTOGENESIS**

145 A possible effect of PG DHC on alveolar bone destruction, which is an essential feature of  
146 periodontitis, has been reported recently. PG DHC lipids were found to promote receptor  
147 activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis by interacting  
148 with non-muscle myosin IIA (Myh9) (29). The latter is an osteoclast cell fusion regulatory cell  
149 protein localized to the cytoplasm of host cells. Myh9 elicited a signal that made Ras-related C3  
150 botulinum toxin substrate 1 (Rac1) upregulate the expression of dendritic cell-specific  
151 transmembrane protein (DC-STAMP). The latter is known as a key osteoclast fusogen that is  
152 responsible for the cell fusion process during osteoclastogenesis. Noteworthy, the process  
153 depended on Rac1/DC-STAMP and not on TLR2/TLR4 engagement. Thus, instead of binding to  
154 TLR2/4 expressed on the cell surface, PG DHC interacted with a cytoskeletal protein that is  
155 localized to the cytoplasm. In addition, non-muscle myosin IIA (Myh9) produced a cell signal  
156 that involved Rac1 to upregulate the expression of DC-STAMP. This key osteoclast fusogen is  
157 responsible for the process of cell fusion during osteoclastogenesis. Further, the study clearly  
158 showed that PG DHC could penetrate cell membranes of osteoclast precursors and enter the  
159 nuclei. This brought significant new insight into the process of macrophage fusion required for  
160 osteoclast formation and promotion of osteoclast-induced bone breakdown associated with the  
161 development of chronic periodontitis.

162

163 **PDHC AND SERINE DIPEPTIDE LIPID INTERFERENCE WITH**  
164 **OSTEOBLAST DIFFERENTIATION AND OTHER CELLULAR EFFECTS**

165

166 Total lipids from *P. gingivalis* and PE DHC and PG DHC lipids prepared free of lipid A were  
167 studied for their effects on primary calvarial osteoblast cultures from mice (30). This  
168 investigation revealed that osteoblast differentiation and fluorescent transgene expression for  
169 calvarial osteoblast differentiation (the transgene for the rat type I collagen promoter fragment  
170 pOBCol2.3GP) (31), were inhibited in a concentration-dependent manner. Osteoblast  
171 proliferation, viability or apoptosis were not markedly affected. Simultaneously, common  
172 osteoblast differentiation genes were downregulated (*Runx2*, *ALP*, *OC*, *BSP*, *OPG* and *DMP-1*)  
173 whereas RANKL, tumor necrosis factor alpha and *MMP-3* genes were upregulated. Mineral  
174 nodule formation *in vitro* was prevented. Total lipids and PE DHC and PG DHC lipid fractions of  
175 *P. gingivalis* also inhibited calvarial osteoblast gene expression and function *in vivo*. These lipid  
176 preparations inhibited osteoblasts through TLR2 engagement, which agrees with observations on  
177 alveolar bone loss in animals infected orally with *P. gingivalis* (32-34). They could therefore act  
178 as a microbial virulence factor in periodontitis by inhibiting osteoblast function and gene  
179 expression. More recent work isolated a serine dipeptide lipid fraction from *P. gingivalis* lipids  
180 using HPLC fractionation with an acidic solvent together with improved HPLC equipment  
181 capable of considerably improved chromatographic resolution. Though serine dipeptide lipids (6,  
182 25) are minor lipid constituents of the total lipids of *P. gingivalis*, this approach allowed the  
183 purification of serine dipeptide lipids essentially free of contaminating phosphorylated  
184 dihydroceramides and other complex lipids. The serine dipeptide lipid class, Lipid 654, has since  
185 been shown to account for the TLR2-dependent inhibition of osteoblast differentiation and  
186 function (25). It was reported that PE DHC lipids of *P. gingivalis* also increased secretion of IL-  
187 6 from dendritic cells *in vitro* (35) and this effect was mediated through engagement of TLR2. It  
188 was later determined using improved HPLC equipment that trace amounts of Lipid 654  
189 contaminating the PE DHC lipid preparation were likely accounting for the TLR2-mediated  
190 effect on dendritic cells (see FIGURE 3) (19). The serine dipeptide lipids may also promote  
191 extraoral inflammatory diseases, e.g., cardiovascular diseases (6). This idea is supported by the  
192 fact that dihydroceramide and serine dipeptide lipids are not only found in gingival tissues but

193 also in human blood, vascular tissue and brain (23). Recently, it was suggested that commensal  
194 Bacteroidetes, to which *P. gingivalis* belongs, that reside in the oral cavity and gut contribute to  
195 the pathogenesis of TLR2-dependent atherosclerosis through deposition and metabolism of serine  
196 dipeptide lipids in artery walls (6). In addition to *P. gingivalis*, the common dental pulpal  
197 pathogen *P. endodontalis*, produces the Lipid 654 class (36). The Lipid 654 preparations isolated  
198 from both *Porphyromonas* species were shown to promote osteoclast formation from RAW  
199 264.7 cells (36) indicating that in addition to sub PG DHC lipids, osteoclast activation is  
200 promoted by serine dipeptide lipids and that bacterial source of Lipid 654 is probably not a  
201 critical issue.

202 Interestingly, phosphorylated dihydroceramide and serine dipeptide lipids have been reported to  
203 contaminate free lipid A isolated from *P. gingivalis* LPS (37) and may be responsible, at least to  
204 some extent for the TLR2-mediated effects of *P. gingivalis* LPS on osteoblasts (38). Regardless,  
205 the PG DHC and serine dipeptide lipids mediate important effects on bone cells and therefore  
206 should be regarded as virulence factors.

207

## 208 PROMOTION OF APOPTOSIS

209 Although *P. gingivalis* dihydroceramides promote inflammatory secretory reactions in  
210 fibroblasts, little is known about their effects on vascular cells. Zhalten et al. (39) studied the  
211 effects of extracted and purified *P. gingivalis* lipids on endothelial cells from the human  
212 umbilical vein. The PG DHC (sub PG DHC) lipid fraction but not the PE DHC lipid fraction of  
213 *P. gingivalis* initiated endothelial cell apoptosis *in vitro*, but not necrosis. PG DHC activated  
214 caspase 3, 6 and 9. Inhibition of these caspases significantly reduced PG DHC-mediated  
215 apoptosis in endothelial cells. Sub PG DHC also induced release of apoptosis-inducing factor.  
216 Pre-incubation of cells with the reactive oxygen species (ROS) scavenger N-acetylcysteine  
217 reduced *P. gingivalis*-induced endothelial apoptosis. Apoptosis was stimulated by exogenous  
218 synthetic sphingosines similar to endogenous mammalian ceramides formed in endothelial and  
219 other cells (39). In addition, *P. gingivalis*-derived lipids were able to induce apparent apoptosis in  
220 gingival fibroblasts (18) similar to apoptosis later reported in gingival fibroblasts when co-  
221 cultured with *P. gingivalis* (40) and in chondrocytes with exposure to *P. gingivalis* itself (41, 42).  
222 It was proposed that lipids from *P. gingivalis* might induce apoptosis in joints even in the absence

223 of live *P. gingivalis* (42), which is noteworthy. The authors also suggested that *P. gingivalis*  
224 lipids could interfere with and impair the repair process in cartilage, thereby linking *P. gingivalis*  
225 to rheumatoid arthritis (42-45).

226

## 227 EXPRESSION AND ANCHORING OF SURFACE POLYSACCHARIDES

228 Moye et al. (46) recently reported that deletion of the PG1780 gene in *P. gingivalis* strain W83  
229 rendered this organism unable to produce dihydroceramide lipids. The PG1780 gene encodes for  
230 the putative serine palmitoyltransferase enzyme of *P. gingivalis*. Serine palmitoyltransferase is  
231 the enzyme responsible for the first step in the synthesis of long chain base precursors of  
232 sphingolipids. Moye et al. (46) showed that the ΔPG1780 mutant is devoid of dihydroceramide  
233 lipids whereas dihydroceramide synthesis was restored in the complemented mutant strain  
234 (ΔPG1780 pTCOW-1780). In addition, electron micrographic evaluation of the ΔPG1780  
235 mutant suggested that surface glycans were diminished. Further evaluation demonstrated that the  
236 ΔPG1780 mutant expressed low levels of K-antigen but showed increased expression of anionic  
237 polysaccharide relative to the W83 parent strain. Of note, the K1 capsule null strain (ΔPG0106)  
238 showed very low expression of both K antigen and anionic polysaccharide when compared with  
239 the ΔPG1780 mutant or parent strain. These results demonstrate that sphingolipid synthesis in *P.*  
240 *gingivalis* is associated with the expression of specific cell surface polysaccharides although the  
241 exact role of sphingolipids in this process remains to be determined. Moye et al. (46) also  
242 demonstrated that lack of sphingolipid synthesis by *P. gingivalis* decreased the expression of cell-  
243 associated arginine (Arg) and lysine (Lys) gingipains (46), the “trypsin like” proteases expressed  
244 by this organism. Bainbridge et al. (48) found that deletion of a 77bpIR element at the 5'end of  
245 the K-antigen capsule synthesis locus of *P. gingivalis* changed the presentation of capsule, O-  
246 LPS, and A-LPS, and reduced cell-associated Arg- and Lys-gingipain activity. This evidence  
247 suggests that sphingolipid synthesis may alter cell surface gingipain expression indirectly though  
248 reduced K antigen expression. Finally, the lipid moiety responsible for covalently anchoring  
249 capsular polysaccharides to the outer membrane has been identified in only a few bacterial  
250 species (47) and includes the direct covalent attachment of capsular polysaccharides to a lyso-  
251 phosphatidylglycerol motif as reported by Willis et al. (47). It is unknown whether capsular

252 polysaccharides are anchored to sphingolipids in *P. gingivalis* cell membranes. Future research is  
253 expected to clarify this possibility.

254

255

## 256 **RESISTANCE TO OXIDATIVE STRESS**

257 Moye et al. (46) reported that the ΔPG1780 sphingolipid-deficient strain of *P. gingivalis* was  
258 more sensitive to oxidative stress after exposure to oxygen even for very short intervals. When  
259 the parental strain and the mutant ΔPG1780 were cultured to early exponential phase and the  
260 cultures were treated with 150–250 μM hydrogen peroxide or water as control, the parental strain  
261 survived the addition of all concentrations of hydrogen peroxide. The mutant cultures treated  
262 with 200 or 250 μM H<sub>2</sub>O<sub>2</sub> were quickly killed and did not recover after 30 h. Cultures of the  
263 mutant strain exposed to the lowest concentration of hydrogen peroxide (150 μM), decreased  
264 initially in density, but recovered by the end of the experiment. This demonstrated that the  
265 ΔPG1780 mutant was much more sensitive to hydrogen peroxide than the parental strain.  
266 Accordingly, sphingolipids seem to play an important role in the resistance of *P. gingivalis* to  
267 oxidative stress and therefore to the survival of this bacterium. A report by An et al. (49)  
268 indicated that sphingolipids are important in *Bacteroides fragilis* protection from oxidative stress.  
269 However, a previous report demonstrated that *B. fragilis* does not produce PG DHC lipids (23),  
270 suggesting that PE DHC sphingolipids may be important in protection of *B. fragilis* from  
271 oxidative stress. Also, other factors can participate in the resistance of *P. gingivalis* to oxidative  
272 damage such as antioxidant enzymes, DNA binding protein (Dps), the hemin layer, enzymatic  
273 removal of deleterious products caused by ROS and response regulators (for a review see (50)).

274

## 275 **ENHANCEMENT OF AUTOIMMUNITY**

276 Phosphorylated dihydroceramides are derived from Bacteroidetes bacteria found in multiple sites  
277 in humans such as the oral cavity, the gastro-intestinal tract and the vagina. These bacterial lipids  
278 could be tipping factors enhancing autoimmunity in man. In a study by Nichols et al., *P.*  
279 *gingivalis* phosphorylated dihydroceramides, particularly PE DHC, significantly increased

280 experimental allergic encephalomyelitis (EAE) in a murine model of multiple sclerosis (35). EAE  
281 was used as a model for autoimmune disease in this study. The increased autoimmune disease  
282 severity resulting from administration of *P. gingivalis* lipids was mediated in a TLR2-dependent  
283 manner. Though the enhanced TLR2-dependent autoimmune response was attributed to PE DHC  
284 lipids, other minor lipid classes of *P. gingivalis*, including the recently described serine dipeptide  
285 lipids, could account for the enhanced engagement of TLR2.

286

## 287 **COMPARATIVE EFFECTS OF SPHINGOLIPIDS IN INFLAMMATORY 288 DISEASES**

289 The distribution of PDHC lipid classes was different in diseased periodontal tissues compared to  
290 tissues from healthy controls (23, 51). The primary dihydroceramide lipids of *P. gingivalis*  
291 recovered from diseased gingival tissue were the unsub PG DHC lipids whereas lesser amounts  
292 of PE DHC and sub PG DHC lipids were detected. PG DHC lipids were also more abundant than  
293 PE DHC lipids on periodontally-diseased teeth (51). This suggested that progression of disease  
294 could be associated with a shift in the PDHCs species released from the microbiota associated  
295 with periodontitis or a shift in the transport or metabolic hydrolysis of specific PDHC lipids in  
296 diseased gingival tissues. PE DHC and PG DHCs also affected gingival fibroblasts differently,  
297 probably due to differences in their polar head groups (18) . As already mentioned, sub PG DHCs  
298 caused fibroblast rounding in culture and increased the production of prostaglandin E<sub>2</sub> with IL-1 $\beta$   
299 co-treatment (18), and promoted apoptosis in endothelial cells (42) and chondrocytes (39). In  
300 contrast, the phosphatidylethanolamine (PEA) lipid fraction did not induce endothelial apoptosis  
301 *in vitro* (42) but did promote cell rounding in gingival fibroblasts (24). Because a homologous  
302 synthetic PEA lipid standard without *isobranched* fatty acids did not cause cell rounding, it was  
303 concluded that the *isobranched* aliphatic chains are also contributing to the apparent cell rounding  
304 of gingival fibroblasts (24). The difference in the biological activity of PG DHC and PE DHC  
305 has been ascribed to the different phosphorylated head group substitution and/or the addition of  
306 esterified *isobranched* C<sub>15:0</sub> fatty acid (18, 51). The interpretation of the relative clinical  
307 importance of dihydroceramides is additionally complicated by the fact that members of other  
308 genera in the oral and intestinal microbiota can produce PDHC lipids such as *Bacteroides*,

309 *Parabacteroides*, *Prevotella*, *Tannerella* and *Porphyromonas* (23). However, none of these  
310 bacteria, except for *T. forsythia*, are considered keystone pathogens in periodontitis.

311

## 312 CONCLUDING REMARKS

313 Sphingolipids are not only structural components of mammalian membranes but have important  
314 functions in specialized membrane domains (lipid rafts and protein complexes) and affect  
315 signaling for a number of cellular processes. Bacterial sphingolipids are similar in structure but  
316 are not identical to human sphingolipids. The importance of sphingolipids in disease has often  
317 been overshadowed by that of LPS, which in the case of *P. gingivalis* LPS can be contaminated  
318 with sphingolipids when prepared by published methods. *P. gingivalis* sphingolipids and serine  
319 dipeptide lipids produce cellular effects particularly relevant to the essential pathological features  
320 of periodontitis including promotion of osteoclastogenesis and inhibition of osteoblast function.  
321 *P. gingivalis* sphingolipids also potentiate prostaglandin secretion from gingival fibroblasts and  
322 are implicated in promoting IL-6 secretion from dendritic cells. These lipids also promote  
323 apoptosis in endothelial cells, potentially contributing to vascular lesions. The latter could be  
324 important in cardiovascular disease since *P. gingivalis* PDHC and serine dipeptide lipids have  
325 been detected in carotid atherosclerotic lesions. However, *P. gingivalis* is not the only organism  
326 responsible for production of dihydroceramide and serine dipeptide lipids since several bacterial  
327 species and genera within members of the Bacteroidetes phylum of the oral cavity, vagina and  
328 intestine may account for these lipids in blood, tissues and brain. Recovery of PDHC lipids in  
329 human brain tissues could occur through transport of PDHC lipids in blood and subsequent  
330 deposition into vascular elements of neural tissues, but could also result from penetration through  
331 the blood brain barrier. Future research will evaluate these possibilities. *P. gingivalis* is not the  
332 sole causal agent in periodontitis either, although it is regarded as the most important keystone  
333 bacterium here. Recently discovered serine dipeptide lipids of *P. gingivalis* have been implicated  
334 in alveolar bone loss in chronic periodontitis and represent a new class of TLR2 ligands with  
335 structural similarity to diacylated lipopeptides. Lipid 430 is highly unusual in that it produces  
336 strong proinflammatory responses and inhibitory effects on osteoblasts, and yet it contains only  
337 one fatty acid acyl chain. Bacterial sphingolipids might also play a role in autoimmune disease  
338 through acute and chronic activation of the immune system e.g., in rheumatoid arthritis and

339 multiple sclerosis. The distribution and composition of DHCs depend on the tissue site and  
340 disease status. This implies that healthy periodontal sites may contain bacterial sphingolipids but  
341 the distribution can be different from that in diseased sites. Since these bacterial sphingolipids  
342 and serine dipeptide lipids are recovered in periodontal and other human tissues and since they  
343 possess important biological properties affecting inflammation and host responses, they should be  
344 classified as virulence factors. Research on the role of these substances in human diseases, which  
345 are only beginning to be understood, should be intensified.

346

#### 347 **ACKNOWLEDGMENTS**

348  
349 FCN acknowledges grants from the National Multiple Sclerosis Society and NIH Grant  
350 DE021055.

351

352

353 **REFERENCES**

- 354 1. Lingwood D, and Simons K. 2010. Lipid rafts as a membrane-organizing principle.  
355 Science 327:46-50.
- 356 2. Nicolson GL. 2014. The fluid-mosaic model of membrane structure: Still relevant to  
357 understanding the structure, function and dynamics of biological membranes after more  
358 than 40 years. Biochim Biophys Acta 1838:1451-1466.
- 359 3. Heaver SL, Johnson EL, and Ley RE. 2018. Sphingolipids in host-microbial interactions.  
360 Curr Opin Microbiol 43:92-99.
- 361 4. Gomi K, Kawasaki K, Kawai Y, Shiozaki M, and Nishijima M. 2002. Toll-like receptor  
362 4-md-2 complex mediates the signal transduction induced by flavolipin, an amino acid-  
363 containing lipid unique to *Flavobacterium meningosepticum*. J Immunol 168:2939-2943.
- 364 5. Nemati R, Dietz C, Anstadt E, Clark R, Smith M, Nichols F, and Yao X. 2017.  
365 Simultaneous determination of absolute configuration and quantity of lipopeptides using  
366 chiral liquid chromatography/mass spectrometry and diastereomeric internal standards.  
367 Anal Chem 89:3583-3589.
- 368 6. Nemati R, Dietz C, Anstadt EJ, Cervantes J, Liu Y, Dewhurst FE, Clark RB, Finegold S,  
369 Gallagher JJ, Smith MB, Yao X, and Nichols FC. 2017. Deposition and hydrolysis of  
370 serine dipeptide lipids of bacteroidetes bacteria in human arteries: Relationship to  
371 atherosclerosis. J Lipid Res 58:1999-2007.
- 372 7. Shiozaki M, Deguchi N, Mochizuki T, Wakabayashi T, Ishikawa T, Haruyama H, Kawai  
373 Y, and Nishijima M. 1998. Revised structure of flavolipin and synthesis of its isomers.  
374 Tetrahedron Lett 39:4497-4500.

- 375 8. Wang M, and Hajishengallis G. 2008. Lipid raft-dependent uptake, signalling and  
376 intracellular fate of *Porphyromonas gingivalis* in mouse macrophages. *Cell Microbiol*  
377 10:2029-2042.
- 378 9. Tsuda K, Amano A, Umebayashi K, Inaba H, Nakagawa I, Nakanishi Y, and Yoshimori  
379 T. 2005. Molecular dissection of internalization of *Porphyromonas gingivalis* by cells  
380 using fluorescent beads coated with bacterial membrane vesicle. *Cell Struct Funct* 30:81-  
381 91.
- 382 10. Tsuda K, Furuta N, Inaba H, Kawai S, Hanada K, Yoshimori T, and Amano A. 2008.  
383 Functional analysis of alpha5beta1 integrin and lipid rafts in invasion of epithelial cells by  
384 *Porphyromonas gingivalis* using fluorescent beads coated with bacterial membrane  
385 vesicles. *Cell Struct Funct* 33:123-132.
- 386 11. Eke PI, Dye BA, Wei L, Slade GD, Thornton-Evans GO, Borgnakke WS, Taylor GW,  
387 Page RC, Beck JD, and Genco RJ. 2015. Update on prevalence of periodontitis in adults  
388 in the united states: Nhanes 2009 to 2012. *J Periodontol* 86:611-622.
- 389 12. Olsen I. 2015. From the acta prize lecture 2014: The periodontal-systemic connection  
390 seen from a microbiological standpoint. *Acta Odontol Scand* 73:563-568.
- 391 13. Olsen I. 2017. Oral microbial dysbiosis precedes development of pancreatic cancer. *J Oral*  
392 *Microbiol* 9:1374148.
- 393 14. Olsen I, and Singhrao SK. 2015. Can oral infection be a risk factor for Alzheimer's  
394 disease? *J Oral Microbiol* 7:29143.
- 395 15. Nichols FC. 1994. Distribution of 3-hydroxy C<sub>17:0</sub> in subgingival plaque and gingival  
396 tissue samples: Relationship to adult periodontitis. *Infect Immun* 62:3753-3760.
- 397 16. Nichols FC, and Maraj B. 1998. Relationship between hydroxy fatty acids and  
398 prostaglandin E<sub>2</sub> in gingival tissue. *Infect. Immun.* 66:5805-5811.

- 399 17. Nichols FC. 1998. Novel ceramides recovered from *Porphyromonas gingivalis*:  
400 Relationship to adult periodontitis. *J. Lipid Res.* 39:2360-2372.
- 401 18. Nichols FC, Riep B, Mun J, Morton MD, Bojarski MT, Dewhirst FE, and Smith MB.  
402 2004. Structures and biological activity of phosphorylated dihydroceramides of  
403 *Porphyromonas gingivalis*. *J Lipid Res* 45:2317-2330.
- 404 19. Clark RB, Cervantes JL, Maciejewski MW, Farrokhi V, Nemati R, Yao X, Anstadt E,  
405 Fujiwara M, Wright KT, Riddle C, La Vake CJ, Salazar JC, Finegold S, and Nichols FC.  
406 2013. Serine lipids of *Porphyromonas gingivalis* are human and mouse toll-like receptor 2  
407 ligands. *Infect Immun* 81:3479-3489.
- 408 20. Nichols FC, Levinbook H, Shnayzman M, and Goldschmidt J. 2001. Prostaglandin E<sub>2</sub>  
409 secretion from gingival fibroblasts treated with interleukin-1beta: Effects of lipid extracts  
410 from *Porphyromonas gingivalis* or calculus. *J Periodontal Res* 36:142-152.
- 411 21. Saglie FR, Smith CT, Newman MG, Carranza FA, Jr., Pertuiset JH, Cheng L, Auil E, and  
412 Nisengard RJ. 1986. The presence of bacteria in the oral epithelium in periodontal  
413 disease. I. Immunohistochemical identification of bacteria. *J Periodontol* 57:492-500.
- 414 22. Sandros J, Papapanou P, and Dahlen G. 1993. *Porphyromonas gingivalis* invades oral  
415 epithelial cells in vitro. *J Periodontal Res* 28:219-226.
- 416 23. Nichols FC, Yao X, Bajrami B, Downes J, Finegold SM, Knee E, Gallagher JJ, Housley  
417 WJ, and Clark RB. 2011. Phosphorylated dihydroceramides from common human  
418 bacteria are recovered in human tissues. *PLoS One* 6:e16771.
- 419 24. Nichols FC, Riep B, Mun J, Morton MD, Kawai T, Dewhirst FE, and Smith MB. 2006.  
420 Structures and biological activities of novel phosphatidylethanolamine lipids of  
421 *Porphyromonas gingivalis*. *J Lipid Res* 47:844-853.

- 422 25. Wang YH, Nemati R, Anstadt E, Liu Y, Son Y, Zhu Q, Yao X, Clark RB, Rowe DW, and  
423 Nichols FC. 2015. Serine dipeptide lipids of *Porphyromonas gingivalis* inhibit osteoblast  
424 differentiation: Relationship to toll-like receptor 2. *Bone*.
- 425 26. Triantafilou M, Morath S, Mackie A, Hartung T, and Triantafilou K. 2004. Lateral  
426 diffusion of toll-like receptors reveals that they are transiently confined within lipid rafts  
427 on the plasma membrane. *J Cell Sci* 117:4007-4014.
- 428 27. Farrokhi V, Nemati R, Nichols FC, Yao X, Anstadt E, Fujiwara M, Grady J, Wakefield D,  
429 Castro W, Donaldson J, and Clark RB. 2013. Bacterial lipodipeptide, lipid 654, is a  
430 microbiome-associated biomarker for multiple sclerosis. *Clin Transl Immunology* 2:e8.
- 431 28. Olsen I, and Jantzen E. 2001. Sphingolipids in bacteria and fungi. *Anaerobe* 7:103-112.
- 432 29. Kanzaki H, Movila A, Kayal R, Napimoga MH, Egashira K, Dewhirst F, Sasaki H,  
433 Howait M, Al-Dharrab A, Mira A, Han X, Taubman MA, Nichols FC, and Kawai T.  
434 2017. Phosphoglycerol dihydroceramide, a distinctive ceramide produced by  
435 *Porphyromonas gingivalis*, promotes RANKL-induced osteoclastogenesis by acting on  
436 non-muscle myosin ii-a (myh9), an osteoclast cell fusion regulatory factor. *Biochim  
437 Biophys Acta* 1862:452-462.
- 438 30. Wang YH, Jiang J, Zhu Q, Alanezi AZ, Clark RB, Jiang X, Rowe DW, and Nichols FC.  
439 2010. *Porphyromonas gingivalis* lipids inhibit osteoblastic differentiation and function.  
440 *Infect Immun* 78:3726-3735.
- 441 31. Kalajzic I, Kalajzic Z, Kaliterna M, Gronowicz G, Clark SH, Lichtler AC, and Rowe D.  
442 2002. Use of type I collagen green fluorescent protein transgenes to identify  
443 subpopulations of cells at different stages of the osteoblast lineage. *J Bone Miner Res*  
444 17:15-25.

- 445 32. Gibson FC, 3rd, and Genco CA. 2007. *Porphyromonas gingivalis* mediated periodontal  
446 disease and atherosclerosis: Disparate diseases with commonalities in pathogenesis  
447 through TLRs. *Curr Pharm Des* 13:3665-3675.
- 448 33. Gibson FC, 3rd, Ukai T, and Genco CA. 2008. Engagement of specific innate immune  
449 signaling pathways during *Porphyromonas gingivalis* induced chronic inflammation and  
450 atherosclerosis. *Front Biosci* 13:2041-2059.
- 451 34. Papadopoulos G, Weinberg EO, Massari P, Gibson FC, 3rd, Wetzler LM, Morgan EF,  
452 and Genco CA. 2013. Macrophage-specific TLR2 signaling mediates pathogen-induced  
453 TNF-dependent inflammatory oral bone loss. *J Immunol* 190:1148-1157.
- 454 35. Nichols FC, Housley WJ, O'Conor CA, Manning T, Wu S, and Clark RB. 2009. Unique  
455 lipids from a common human bacterium represent a new class of Toll-like receptor 2  
456 ligands capable of enhancing autoimmunity. *Am J Pathol* 175:2430-2438.
- 457 36. Mirucki CS, Abedi M, Jiang J, Zhu Q, Wang YH, Safavi KE, Clark RB, and Nichols FC.  
458 2014. Biologic activity of *Porphyromonas endodontalis* complex lipids. *J Endod* 40:1342-  
459 1348.
- 460 37. Nichols FC, Bajrami B, Clark RB, Housley W, and Yao X. 2012. Free lipid A isolated  
461 from *Porphyromonas gingivalis* lipopolysaccharide is contaminated with phosphorylated  
462 dihydroceramide lipids: Recovery in diseased dental samples. *Infect Immun* 80:860-874.
- 463 38. Kassem A, Henning P, Lundberg P, Souza PP, Lindholm C, and Lerner UH. 2015.  
464 *Porphyromonas gingivalis* stimulates bone resorption by enhancing RANKL (receptor  
465 activator of NF-kappaB ligand) through activation of Toll-like receptor 2 in osteoblasts. *J  
466 Biol Chem* 290:20147-20158.

- 467 39. Zahlten J, Riep B, Nichols FC, Walter C, Schmeck B, Bernimoulin JP, and Hippenstiel S.  
468 2007. *Porphyromonas gingivalis* dihydroceramides induce apoptosis in endothelial cells. *J*  
469 *Dent Res* 86:635-640.
- 470 40. Desta T, and Graves DT. 2007. Fibroblast apoptosis induced by *Porphyromonas*  
471 *gingivalis* is stimulated by a gingipain and caspase-independent pathway that involves  
472 apoptosis-inducing factor. *Cell Microbiol* 9:2667-2675.
- 473 41. Rohner E, Detert J, Kolar P, Hocke A, N'Guessan P, Matziolis G, Kanitz V, Bernimoulin  
474 JP, Kielbassa A, Burmester GR, Buttgereit F, and Pisched N. 2010. Induced apoptosis of  
475 chondrocytes by *Porphyromonas gingivalis* as a possible pathway for cartilage loss in  
476 rheumatoid arthritis. *Calcif Tissue Int.*
- 477 42. Rohner E, Hoff P, Matziolis G, Perka C, Riep B, Nichols FC, Kielbassa AM, Detert J,  
478 Burmester GR, Buttgereit F, Zahlten J, and Pisched N. 2012. The impact of  
479 *Porphyromonas gingivalis* lipids on apoptosis of primary human chondrocytes. *Connect*  
480 *Tissue Res* 53:327-333.
- 481 43. de Pablo P, Chapple IL, Buckley CD, and Dietrich T. 2009. Periodontitis in systemic  
482 rheumatic diseases. *Nat Rev Rheumatol* 5:218-224.
- 483 44. de Pablo P, Dietrich T, and McAlindon TE. 2008. Association of periodontal disease and  
484 tooth loss with rheumatoid arthritis in the us population. *J Rheumatol* 35:70-76.
- 485 45. Kaur S, White S, and Bartold PM. 2013. Periodontal disease and rheumatoid arthritis: A  
486 systematic review. *J Dent Res* 92:399-408.
- 487 46. Moye ZD, Valiuskyte K, Dewhurst FE, Nichols FC, and Davey ME. 2016. Synthesis of  
488 sphingolipids impacts survival of *Porphyromonas gingivalis* and the presentation of  
489 surface polysaccharides. *Front Microbiol* 7:1919.

- 490 47. Willis LM, Stupak J, Richards MR, Lowary TL, Li J, and Whitfield C. 2013. Conserved  
491 glycolipid termini in capsular polysaccharides synthesized by ATP-binding cassette  
492 transporter-dependent pathways in Gram-negative pathogens. Proc Natl Acad Sci U S A  
493 110:7868-7873.
- 494 48. Bainbridge BW, Hirano T, Grieshaber N, and Davey ME. 2015. Deletion of a 77-base-  
495 pair inverted repeat element alters the synthesis of surface polysaccharides in  
496 *Porphyromonas gingivalis*. J Bacteriol 197:1208-1220.
- 497 49. An D, Na C, Bielawski J, Hannun YA, and Kasper DL. 2011. Membrane sphingolipids as  
498 essential molecular signals for *Bacteroides* survival in the intestine. Proc Natl Acad Sci U  
499 S A 108 Suppl 1:4666-4671.
- 500 50. Henry LG, McKenzie RM, Robles A, and Fletcher HM. 2012. Oxidative stress resistance  
501 in *Porphyromonas gingivalis*. Future Microbiol 7:497-512.
- 502 51. Nichols FC, and Rojanasomith K. 2006. *Porphyromonas gingivalis* lipids and diseased  
503 dental tissues. Oral Microbiol Immunol 21:84-92.
- 504
- 505

506 **FIGURE LEGENDS**

507

508 **FIGURE 1** Model for phosphorylated dihydroceramide and serine dipeptide lipid penetration  
509 into gingival tissues and relevant biological effects in the expression of chronic periodontitis. (1)  
510 The serine dipeptide parent lipid, Lipid 654, is recovered in subgingival calculus and subgingival  
511 plaque. Lipid 654 promotes osteoclast formation from RAW cells, inhibits osteoblast  
512 differentiation and function, and is implicated in dendritic cell release of IL-6. (2) Lipid 654 can  
513 be de-esterified by mammalian phospholipase A2 (PLA2) enzymes, thus producing within  
514 gingival tissues another serine dipeptide lipid, Lipid 430. Lipid 430 inhibition of osteoblast  
515 differentiation and function occurs at lower levels when compared with Lipid 654. (3)  
516 Phosphorylated dihydroceramide lipids (PDHCs) including PE DHC, sub PG DHC and unsub PG  
517 DHC lipids (see **FIGURE 2**), are abundant in lipid extracts of subgingival calculus, but are also  
518 recovered in subgingival plaque and gingival tissues. (4) Sub PG DHC lipids promote IL-1 $\beta$ -  
519 mediated prostaglandin production in gingival fibroblasts and cell fusion during  
520 osteoclastogenesis of RAW cells. (5) Sub PG DHC lipids promote gingival fibroblast cell death  
521 in culture. Penetration of sub PG DHC lipids through junctional epithelium could therefore  
522 promote fibroblast cell death along the tooth root surface.


523 **FIGURE 2** Structures of novel *P. gingivalis* dihydroceramide and phospholipids (<sup>a</sup> adapted from  
524 (18), <sup>b</sup> from (51), <sup>c</sup> from (17) and <sup>d</sup> from (24)). \*The long chain bases vary from 17 to 19 carbons  
525 in length. The 17 and 19 carbon long chain bases are *isobranched* as shown but the 18 carbon  
526 long chain base exists as a straight aliphatic chain. Note the *isobranched* saturated fatty acids  
527 (C<sub>15:0</sub> and C<sub>13:0</sub>) in phosphatidylethanolamine (PEA) lipids.

528

529 **FIGURE 3** Structures of serine dipeptide lipids from *P. gingivalis* (adapted from (7, 19)). \*Lipid  
530 654 was originally described in *Flavobacterium meningosepticum* and was termed Flavolipin by  
531 Shiozaki et al. (7).  
532

533 **FIGURE 1.**

534




535

ScEYEnce Studios  
ASM Journals  
MMBR00035-18  
Dr. Nichols  
Figure: 01

536 **FIGURE 2.**

537


**Novel *P. gingivalis* Dihydroceramide and Phospholipids**

538

539

540 **FIGURE 3.**

541



542

543

544 **TABLE 1** Lipid abbreviations

545

---

546	DHC	Dihydroceramide
547	PE DHC	Phosphoethanolamine dihydroceramide
548	PG DHC	Phosphoglycerol dihydroceramide
549	PDHCs	Phosphorylated dihydroceramides
550	Sub PG DHC	Substituted phosphoglycerol dihydroceramide
551	Unsub PG DHC	Unsubstituted phosphoglycerol dihydroceramide
552	PEA	Phosphatidylethanolamine

---

553

554

555

556